Santen Pharmaceutical Co., Ltd.

Text Size
  • Small
  • Medium
  • Large


Our Partners

Our Partners Our Partners
Through a history of successful collaborations, Santen has built global alliances with venture businesses, universities, research centers, and other pharmaceutical companies. Each partnership continues to bring us closer toward our mission in meeting the needs of ophthalmic patients worldwide.
The following examples illustrate several of our recent successful alliances with our partners.

  • Aug. 2016

  • InnFocus, Inc.
    InnFocus, Inc.

    Santen completed the acquisition of InnFocus, Inc., developer of the InnFocus MicroShunt®, glaucoma implant device.

  • Mar. 2016

  • AYUMI Pharmaceutical

    Santen and ONO entered into an exclusive license agreement whereby Santen will develop and commercialize ONO-9054, an FP/EP3 dual agonist for the treatment for glaucoma and ocular hypertension developed by ONO, on a worldwide basis.

  • Aug. 2015

  • AYUMI Pharmaceutical
    Ayumi Pharmaceutical Corporation

    Santen announced the completion of the transfer of anti-rheumatic pharmaceuticals business to Ayumi Pharmaceutical Corporation.

  • May. 2014

    Merck & Co., Inc., Kenilworth, N.J., U.S.A.

    Santen and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (Merck, known as MSD outside of the United States and Canada) signed an agreement for the purchase of ophthalmology products.

  • Apr. 2014

    Akorn Inc./Oak Pharmaceuticals, Inc.

    Santen and Oak Pharmaceuticals, Inc., a subsidiary of Akorn, Inc. entered into a license agreement for sales and marketing of ZIOPTAN® in the US market.

  • Mar. 2014

    TRACON Pharmaceuticals, Inc.

    Santen and TRACON Pharmaceuticals, Inc. entered into a license agreement for the development of TRC105 (anti-endoglin antibody) in ophthalmology.

  • Sep. 2012

  • Eisai Co., Ltd.
    Eisai Co., Ltd.

    Santen and Eisai Co., Ltd. entered into an option agreement for the rights of evaluation and first negotiation for Eisai-owned compounds in the field of ophthalmology.

  • May. 2012

    Bayer Yakuhin, Ltd.

    Santen and Bayer Yakuhin, Ltd. concluded an agreement of co-promotion of EYLEA® (aflibercept intravitreal injection) in Japan.

  • Oct. 2011

  • UBE
    Ube Industries, Ltd.

    Santen and Ube Industries, Ltd. entered into a collaboration to develop and commercialize Ubeís EP2 agonist compound for glaucoma treatment.

  • Oct. 2011

  • Novagali Pharma S.A.

    Santen completed the acquisition of a controlling interest in Novagali Pharma S.A. (currently known as Santen S.A.S.)

  • Feb. 2011

  • UBE
    Nippon Boehringer Ingelheim Co., Ltd.

    Santen and Nippon Boehringer Ingelheim Co., Ltd. entered into an agreement to develop and commercialize epinastine eye drops (trademark: ALESION® ) for allergic conjunctivitis in Japan.